期刊文献+

结直肠癌肝转移的手术治疗探讨 被引量:1

Surgical Resection for Colorectal Carcinoma Metastatic to the Liver
下载PDF
导出
摘要 目的探讨结直肠癌肝转移的外科手术治疗效果。方法对41例结直肠癌肝转移患者施行手术切除,综合文献对手术适应证、手术方式及随访结果进行分析,并比较同期手术组与非同期手术组的生存率。结果全组无手术死亡,1、3、5年生存率分别为82.9%、46.3%、17.1%,同期手术组与非同期手术组1、3、5年生存率比较差异无显著性。结论手术切除是结直肠癌肝转移的有效治疗方法。 Objective To study the effect of surgical resection for colorectal carcinoma metastatic to the liver.Methods 41 cases with colorectal carcinoma metastatic to the liver were received surgical resection. The clinical data were analyzed retrospectively. We reviewed the literature and studied the surgical indications, operating modes and the follow-up results. And the survival rates were compared between the same time surgery group and the different time surgery group.Results All the cases recovered smoothly after operation. No case died during the operation. The 1, 3 and 5-year survival rates were 82.9%, 46.3%, 17.1% respectively. There was no significant difference between the same time surgery group and the different time surgery group.Conclusion Surgical resection is the most effective method for colorectal carcinoma metastatic to the liver.
出处 《医学新知》 CAS 2007年第1期20-21,24,共3页 New Medicine
关键词 结直肠癌 肝转移 手术治疗 colorectal carcinoma hepatic metastases surgical resection
  • 相关文献

参考文献8

  • 1Bramhall S R,Gur U,Coldham C,et al.Liver resectionfor colorectal metastases.Ann R Coll Surg,2003,85(5):334. 被引量:1
  • 2Philipp M K,Debabrata B,Nancy K,et al.Moleculartherapies for colorectal cancer metastatic to the liver.Mol Ther,2002,5(5):492. 被引量:1
  • 3Fong Y,Fortner J,Sun R L,et al.Clinical score forpredicting recurrence after hepatic resection for metastaticcolorectal cancer:Analysis of 1001 consecutive case.Ann Surg,1999,230(3):309. 被引量:1
  • 4Nordlinger B,Guiguet M,Vallant J C,et al.Surgicalresection on colorectal carcinoma metastases to theliver,a prognostic scoring system to improve caseselection based on 1568 patients.Cancer,1996,77(7):1254. 被引量:1
  • 5Robert M,Philip P,Yuman F,et al.Simultabeous liverand colorectal resections are safe for synchronouscolorectal liver metastasis.J AM Coll Surg,2003,197:233. 被引量:1
  • 6Fong Y.Hepatic colorectal metastasis:Current surgicaltherapy,selection criteria for hepatectomy,and role foradjuvant therapy.Advances in Surgery,2000,34(3):351. 被引量:1
  • 7傅德良.结肠直肠癌肝转移重复肝切除后生存不佳的预后因素[J].国外医学(外科学分册),2004,31(2):120-121. 被引量:1
  • 8季加孚.结直肠癌肝转移的治疗策略[J].中国实用外科杂志,2004,24(7):398-400. 被引量:26

二级参考文献12

  • 1Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg, 2003, 197(2): 233-291 被引量:1
  • 2Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg, 1984, 199(5): 502-508 被引量:1
  • 3Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol, 被引量:2
  • 4Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 2001, 19(21): 4097-4106 被引量:1
  • 5Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol, 2000, 45(4): 291-297 被引量:1
  • 6Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998, 352(9138): 1407-1412 被引量:1
  • 7Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998, 352(9138): 1413-1418 被引量:1
  • 8Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 a 被引量:1
  • 9Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 2000, 343(13): 905-914 被引量:1
  • 10de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer, 1997, 33(2): 214-219 被引量:1

共引文献25

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部